Giuseppe Barbesino, MD

Articles by Giuseppe Barbesino, MD

Novel Treatment Advances in Differentiated Thyroid Cancer

ByLori J. Wirth, MD,Marcia Brose, MD, PhD, FASCO,Naifa L. Busaidy, MD, FACP, FACE,Maria E. Cabanillas, MD,Giuseppe Barbesino, MD

February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

ByLori J. Wirth, MD,Maria E. Cabanillas, MD,Giuseppe Barbesino, MD

February 3rd 2022

The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.

Giuseppe Barbesino, MD

Articles by Giuseppe Barbesino, MD

Novel Treatment Advances in Differentiated Thyroid Cancer

BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer

Latest Updated Articles

Trending on OncLive

Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC

Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC

Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC

Surufatinib Plus Serplulimab and Chemo Shows Activity in First-Line Extrapulmonary NEC